We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
高シグナルの見出しのみ — マクロイベント、決算、M&A、規制。リスト記事とアナリストのクリックベイトはデフォルトでフィルタ。1時間ごとに更新。
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends of the investing world.
Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the
Gilead Sciences began 2026 with revenue and adjusted earnings per share both exceeding Wall Street expectations, reflecting strong commercial execution and demand across its core franchises. Management highlighted robust performance in the HIV segment, particularly from Biktarvy and the PrEP portfolio, as well as continued momentum in oncology with Trodelvy and rapid growth from newly launched products like Yes2Go. CEO Daniel O’Day pointed to disciplined financial management and recent product l
Compugen Ltd. (NASDAQ:CGEN) shares jumped more than 18% in premarket trading on Monday after the biotechnology company reported first-quarter revenue ahead of analyst expectations, despite posting a slightly wider-than-expected quarterly loss.
Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation through recent acquisitions and pipeline development. Speaking at the Bank of America Healthca
Gilead Sciences (GILD) is back in focus after a busy stretch that combined stronger than expected first quarter results, sharply revised full year loss guidance tied to acquisition related charges, and a priority FDA review for a new HIV regimen. See our latest analysis for Gilead Sciences. Even with the recent news flurry around Q1 results, revised guidance and fresh bond issues, Gilead Sciences' share price has eased in the short term, with a 30 day share price return of 7.29% and a 90 day...
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of directors Alexis Borisy and Kanishka Pothula, with Sung Lee appointed Lead Independent Director. Alongside a cash balance of about US$380 million expected to fund operations into 2028, the company is refocusing its oncology pipeline by prioritizing MTAP-deleted selective PRMT5 programs and...
Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion, emphasizing programs in herpes simplex virus, hepatitis D and transplant-related herpes viruses. Gaggar describe
Spiking energy prices have pushed inflation to a three-year high of 3.8%. Investors expect price pressures related to the Iran war to ease—one reason the stock market keeps chugging along. Retirees who collect Social Security should get a bigger raise next year.
Based on the average brokerage recommendation (ABR), Gilead (GILD) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported revenue ahead of Wall Street’s expectations in Q1 CY2026, with sales up 4.4% year on year to $6.96 billion. The company expects the full year’s revenue to be around $30.2 billion, close to analysts’ estimates. Its non-GAAP profit of $2.03 per share was 6.3% above analysts’ consensus estimates.
We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Gilead Sciences, Inc. is among the best cancer stocks to invest in. TheFly reported on May 7 that GILD revised its fiscal 2026 outlook, now expecting adjusted earnings per share between a loss of $1.05 and a loss […]
Gilead Sciences, Inc. ( NASDAQ:GILD ) last week reported its latest quarterly results, which makes it a good time for...
Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the shares. The firm cited elevated conviction for the PRMT5 inhibitor + RAS(ON) inhibitor synergy in pancreatic […]
In early May 2026, Gilead Sciences reported first-quarter 2026 results showing revenue of US$6.96 billion and net income of US$2.02 billion, alongside updated guidance that pairs higher expected product sales with an adjusted full-year earnings loss driven by very large acquisition-related charges. At the same time, Gilead advanced its HIV portfolio with FDA priority review for the once-daily bictegravir/lenacapavir combination and continued returning capital through share repurchases, even...
Biktarvy continues to be a strong growth asset for Gilead, while Yeztugo’s launch rides an upward trajectory.
Gilead Sciences (GILD) raised Yeztugo guidance for 2026 to $1 billion from $800 million, which is "g
GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.
As we execute on the strongest pipeline in our history, Gilead Sciences, Inc. is also taking steps to further strengthen the company's position for the future. The ongoing success of the Esthugo launch is a key driver of this growth in HIV prevention, with first quarter sales growing 72% sequentially. Looking forward, with no major LOEs until 2036, Gilead Sciences, Inc.'s HIV business is poised for strong, durable growth supported by up to seven potential new HIV product launches by 2033.
Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones across HIV, oncology, liver disease, and inflammation. Executives repeatedly pointed to “consistent
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Gilead (GILD) delivered earnings and revenue surprises of +7.68% and +0.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences beat analysts’ earnings and revenue expectations in its latest quarter. Gilead logged adjusted earnings of $2.03 a share, ahead of the $1.91 consensus among analysts polled by FactSet. Gilead’s top-line growth rested heavily on Biktarvy, its blockbuster HIV treatment, which accounted for nearly half of total revenue as sales rose 8% to $3.4 billion.
Galapagos (NASDAQ:GLPG) executives used the company’s first-quarter 2026 earnings call to highlight what Chief Executive Officer Henry Gosebruch described as a “real transformation,” including portfolio changes, management and board updates, and an upcoming corporate rebrand to Lakefront Biotherapeu
The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 4.4% year on year to $6.96 billion. The company expects the full year’s revenue to be around $30.2 billion, close to analysts’ estimates. Its non-GAAP profit of $2.03 per share was 6.3% above analysts’ consensus estimates.
Gilead Sciences issued a mixed guidance update late Thursday after the biotech company beat first-quarter sales expectations.
By Deena Beasley LOS ANGELES, May 7 (Reuters) - Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said it now expects a loss for
